InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,993.60
(
0.34%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
-0.20%
)
Bitcoin
60,638.21
(
4.30%
)
Post# of 253119
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120431
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 150608

Monday, 10/15/2012 4:29:46 PM

Monday, October 15, 2012 4:29:46 PM

Post# of 253119
The late relapses you’re referring to occurred in the PILOT study, which tested ABT-450/r + ABT-072 (a non-nuke) + ribavirin; i.e. it had no NS5A inhibitor. The study we’re discussing today, called AVIATOR, tested ABT-450/r + ABT-267 (a newer non-nuke than ABT-072) + ABT-333 (NS5A) + ribavirin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up